People with myasthenia gravis (MG) tend to have fewer hospitalizations and less need for corticosteroids after starting treatment with Rystiggo (rozanolixizumab-noli), according to an analysis of insurance claims data from the U.S. Corticosteroids are anti-inflammatory medications commonly used in MG, “but long-term use is associated with a…
News
An eyedrop formulation of neostigmine, an acetylcholinesterase inhibitor (AChEI) whose oral formulation was once a mainstay treatment for myasthenia gravis (MG), may safely reduce drooping eyelids in people with the neuromuscular disease. That’s according to data from a small Phase 1 clinical trial (ACTRN12624000545561), which showed that one…
Being pregnant does not increase the risk of hospitalizations for women with myasthenia gravis (MG), a study in Sweden found. Findings also indicate that the risk of MG-related hospitalization is not significantly increased after birth. However, for the minority of patients who are hospitalized during this period, these hospitalizations…
A high-fat, low-carbohydrate ketogenic diet may significantly reduce muscle weakness and fatigue for people living with generalized myasthenia gravis (gMG), according to a new pilot clinical trial. Patients who followed the “keto” regimen for 12 weeks saw clinically meaningful improvements in their physical symptoms compared to those who stuck…
The Myasthenia Gravis Foundation of America (MGFA) awarded four grants, each valued at $110,000, to research projects aimed at better understanding the biology of myasthenia gravis (MG) and improving its diagnosis and treatment. “MGFA is helping to fuel a sea change in myasthenia gravis diagnosis and care,” Samantha…
Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) are now approved in the U.S. to treat all adults with generalized myasthenia gravis (gMG), regardless of antibody status. The U.S. Food and Drug Administration (FDA) initially approved Vyvgart in 2021 and Vyvgart Hytrulo in…
Dianthus Therapeutics is on track to launch by midyear a late-stage clinical trial to confirm the safety and effectiveness of claseprubart (DNTH103), its experimental injection therapy, in people with generalized myasthenia gravis (gMG). The Phase 3 study, called EMERGE, will be registrational, meaning it will be designed to…
Switching from intravenous immunoglobulin (IVIG) to Vyvgart (efgartigimod alfa) was associated with fewer hospitalizations and better quality-of-life scores after the switch in people with generalized myasthenia gravis (gMG), according to a study in Japan. Also, a greater proportion of patients transitioning to Vyvgart achieved minimal manifestations, a…
The National Institute for Health and Care Excellence (NICE) has recommended that Rystiggo (rozanolixizumab-noli) be covered by England’s National Health Service (NHS) and provided at low or no cost to certain adults with hard-to-treat generalized myasthenia gravis (gMG). The recommendation makes Rystiggo the first gMG therapy to be…
A thymectomy, the surgical removal of the thymus gland, was projected to improve health outcomes and lower lifetime care costs when added to prednisolone-based care for eligible adults with myasthenia gravis (MG) in the U.K. Simulations in the study, which focused on eligible adults with generalized MG and…
Recent Posts
- I’d like to make a movie about what living with myasthenia gravis is like
- Study ties Rystiggo to fewer hospital stays, less corticosteroid need
- Neostigmine eyedrops may ease drooping of eyelids in MG patients
- Patients shouldn’t have to struggle so much because of healthcare costs
- Study has ‘wonderful news’ for MG patients considering pregnancy